The Roblox vision for bringing people together
through shared experiences, plus the Akili commitment to a new era
of cognitive medicine, make the companies ideal partners to deliver
a reimagined patient experience
Akili Interactive (“Akili”), a leading digital medicine company
pioneering the development of cognitive treatments through
game-changing technologies, and Roblox (NYSE: RBLX), a global
platform bringing millions of people together through shared
experiences, today announced a collaboration that connects
patients' medical treatments to their favorite virtual worlds.
“Roblox brings together tens of millions of people every day to
connect, create, and express themselves, and we’re proud to be
working with Akili to leverage that passion and enjoyment in
connection with their first-in-class digital treatment,” said Craig
Donato, Chief Business Officer of Roblox. “Akili has captured our
imagination with its prescription treatment for children with ADHD
delivered through an action video game experience and shares our
vision and enthusiasm for what’s possible through interactive,
digital experiences. We’re proud to help them as they lead the
effort to realize new potential in the field of medicine.”
Through this partnership, Akili and Roblox are introducing new
ways for medicine to fit into patients’ lives. Initially, the
companies will establish an exclusive Roblox rewards exchange tied
to Akili’s EndeavorRx® treatment (see full indication below). The
companies are exploring additional novel approaches and
opportunities to engage Akili patients through Roblox
integrations.
“We are committed to improving the world’s cognitive health
through treatments that engage and wow patients,” said Eddie
Martucci, CEO and Co-Founder of Akili Interactive. “Our FDA-cleared
video game treatment demonstrates that medicine can be enjoyable,
and that is only the beginning. Akili’s long-term vision aims to
integrate digital medicine into patients’ daily lives in ways never
before seen or experienced. Roblox has changed how millions learn,
work, connect and play, and we are excited to work together to
further push the boundaries of our industries and continue to
redefine the experience of medicine.”
Akili and Roblox are natural partners. Akili has challenged
traditional perceptions of medicine and created EndeavorRx®, the
first and only prescription video game treatment for children with
ADHD, cleared by the U.S. Food and Drug Administration (FDA). With
more than 55 million people worldwide coming together on Roblox
every day, Roblox is powering a platform for immersive, 3D shared
experiences. Together, they have the ability to reimagine the
patient experience.
EndeavorRx® Indication and Overview
EndeavorRx® is indicated to improve attention function as
measured by computer-based testing in children ages 8 to 12 years
old with primarily inattentive or combined-type ADHD, who have a
demonstrated attention issue. Patients who engage with EndeavorRx®
demonstrate improvements in a digitally assessed measure Test of
Variables of Attention (TOVA®) of sustained and selective attention
and may not display benefits in typical behavioral symptoms, such
as hyperactivity. EndeavorRx® should be considered for use as part
of a therapeutic program that may include clinician-directed
therapy, medication, and/or educational programs, which further
address symptoms of the disorder. EndeavorRx® is available by
prescription only. It is not intended to be used as a stand-alone
therapeutic and is not a substitution for a child’s medication.
EndeavorRx® associated adverse events in clinical trials included
frustration (6.1%), headache (1.3%), dizziness (0.6%), emotional
reaction (0.4%), nausea (0.4%), and aggression (0.2%). No serious
adverse events were associated with its use. EndeavorRx® is
recommended to be used for approximately 25 minutes a day, 5 days a
week, over initially at least 4 consecutive weeks, or as
recommended by your child’s health care provider. To learn more
about EndeavorRx®, please visit EndeavorRx.com.
About Roblox
Roblox is reimagining the way people come together to connect,
create and express themselves through immersive, interactive shared
experiences. Every day, millions of people around the world play,
learn, communicate, and expand their friendships as they explore
millions of user-generated digital experiences, all built by
creators on the platform. Our mission is to connect billions of
users with civility and optimism and support a safe and diverse
community — one that inspires and fosters creativity and positive
relationships among people around the world. For more information,
please visit corp.roblox.com.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Our approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine – medicine that is validated through
clinical trials like a drug or medical device but experienced like
entertainment. Akili’s platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili’s belief that
effective medicine can also be fun and engaging, Akili’s products
are delivered through captivating action video game experiences.
For more information, please visit www.akiliinteractive.com.
Forward-Looking Statements
This communication may contain certain forward-looking
statements within the meaning of the federal securities laws. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions and include statements regarding Akili’s
expectations for EndeavorRx® and digital medicine, its partnership
with Roblox and the benefits expected therefrom. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
communication, including but not limited to (i) the ability of
Akili to successfully commercialize EndeavorRx® and continue to
advance its clinical development pipeline, (ii) the ability of
Akili to maintain relationships with customers and suppliers and
retain its management and key employees, (iii) the evolution of the
markets in which Akili competes, (iv) the ability of Akili to
defend its intellectual property and satisfy regulatory
requirements, (v) the impact of the COVID-19 pandemic on Akili’s
business, (vi) Akili’s expectations regarding its market
opportunities and (vii) the risk of downturns and a changing
regulatory landscape in the highly competitive industry in which
Akili operates. The foregoing list of factors is not exhaustive.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Akili assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Akili does
not give any assurance that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220524006097/en/
Akili Julie DiCarlo
julie@akiliinteractive.com
Roblox Samantha Spielman sspielman@roblox.com
Grafico Azioni Social Capital Suvretta ... (NASDAQ:DNAA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Social Capital Suvretta ... (NASDAQ:DNAA)
Storico
Da Giu 2023 a Giu 2024